OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
OptimizeRx Corp (OPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q2 revenue totals $20.5 million - Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively - Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million
How this was made
The 30-second read
Why it matters
Traders can update models using the reported Q2 revenue, GAAP and non-GAAP profitability, adjusted EBITDA, cash balance, and the reiterated FY2026 revenue and adjusted EBITDA ranges. The debt refinancing and term-loan paydown may reduce near-term financial risk, but the YoY revenue contraction and retention deterioration are key watch items.
Market read
A primary earnings and guidance disclosure with concrete financial figures and balance-sheet actions, likely to drive near-term repricing versus prior expectations.
What to watch
Top-20 customer concentration fell (54% vs 59%), but net revenue retention dropped to 90% from 121%, which could imply churn or pricing pressure despite platform investment.
Background
OptimizeRx filed an SEC Form 8-K with its Q2 2026 results and FY2026 guidance reiteration, plus a debt refinancing update and director/officer compensation item.
Ticker impact
OptimizeRx reported Q2 2026 revenue of $20.5M, GAAP net loss of $0.7M, and reiterated FY2026 guidance to $95M-$100M revenue and $21M-$25M adjusted EBITDA.
Near-term bias modestly positive if investors focus on guidance reiteration and margin expansion, but tempered by the 30% YoY revenue decline.
This is a primary earnings/guidance disclosure in an 8-K, including specific KPIs, cash balance, and refinancing details. However, the article also highlights YoY revenue contraction and retention deterioration, which can cap upside.
Market effects
Signals demand-side healthcare marketing tech demand and AI-enabled audience tooling traction, but does not change sector fundamentals broadly.
Limited, as the disclosure is company-specific with no stated regional policy or procurement changes.
Low, as the guidance and refinancing are domestic and not tied to global regulatory or macro events.
Counterpoint
The company’s narrative of margin expansion may not offset the reported 30% YoY revenue decline and lower net revenue retention, suggesting growth quality is weakening.
Key entities
- companyOptimizeRx Corp
Nasdaq-listed healthcare technology provider reporting Q2 2026 results and reiterating FY2026 guidance in an 8-K.
- personStephen L. Silvestro
CEO quoted on Q2 performance, margin expansion, platform advancements, and balance-sheet paydown.
